These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 35335891)

  • 21. Clinical and immunological effects of mRNA vaccines in malignant diseases.
    Heine A; Juranek S; Brossart P
    Mol Cancer; 2021 Mar; 20(1):52. PubMed ID: 33722265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRNA vaccine delivery using lipid nanoparticles.
    Reichmuth AM; Oberli MA; Jaklenec A; Langer R; Blankschtein D
    Ther Deliv; 2016; 7(5):319-34. PubMed ID: 27075952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Status and Future Perspectives on MRNA Drug Manufacturing.
    Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
    Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
    Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of rational design of mRNA-based therapeutics and vaccines.
    To KKW; Cho WCS
    Expert Opin Drug Discov; 2021 Nov; 16(11):1307-1317. PubMed ID: 34058918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent Advances in the Noninvasive Delivery of mRNA.
    Qin M; Du G; Sun X
    Acc Chem Res; 2021 Dec; 54(23):4262-4271. PubMed ID: 34756014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mRNA delivery technologies: Toward clinical translation.
    Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
    Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mRNA-based cancer therapeutics.
    Liu C; Shi Q; Huang X; Koo S; Kong N; Tao W
    Nat Rev Cancer; 2023 Aug; 23(8):526-543. PubMed ID: 37311817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-liver mRNA Delivery.
    Loughrey D; Dahlman JE
    Acc Chem Res; 2022 Jan; 55(1):13-23. PubMed ID: 34859663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy.
    Duan LJ; Wang Q; Zhang C; Yang DX; Zhang XY
    Front Immunol; 2022; 13():923647. PubMed ID: 35711457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RNA-Based Vaccines in Cancer Immunotherapy.
    McNamara MA; Nair SK; Holl EK
    J Immunol Res; 2015; 2015():794528. PubMed ID: 26665011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advanced nanoscale delivery systems for mRNA-based vaccines.
    Mobasher M; Ansari R; Castejon AM; Barar J; Omidi Y
    Biochim Biophys Acta Gen Subj; 2024 Mar; 1868(3):130558. PubMed ID: 38185238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety.
    Vlatkovic I
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34068715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications.
    Patel S; Athirasala A; Menezes PP; Ashwanikumar N; Zou T; Sahay G; Bertassoni LE
    Tissue Eng Part A; 2019 Jan; 25(1-2):91-112. PubMed ID: 29661055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immuno-engineered mRNA combined with cell adhesive niche for synergistic modulation of the MSC secretome.
    Drzeniek NM; Kahwaji N; Schlickeiser S; Reinke P; Geißler S; Volk HD; Gossen M
    Biomaterials; 2023 Mar; 294():121971. PubMed ID: 36634491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy.
    Copur M
    Oncology (Williston Park); 2021 Apr; 35(4):190-198. PubMed ID: 33893760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development.
    Ilyichev AA; Orlova LA; Sharabrin SV; Karpenko LI
    Vavilovskii Zhurnal Genet Selektsii; 2020 Nov; 24(7):802-807. PubMed ID: 33959697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives.
    Gómez-Aguado I; Rodríguez-Castejón J; Vicente-Pascual M; Rodríguez-Gascón A; Solinís MÁ; Del Pozo-Rodríguez A
    Nanomaterials (Basel); 2020 Feb; 10(2):. PubMed ID: 32093140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in mRNA-based drug discovery in cancer immunotherapy.
    Di Trani CA; Fernandez-Sendin M; Cirella A; Segués A; Olivera I; Bolaños E; Melero I; Berraondo P
    Expert Opin Drug Discov; 2022 Jan; 17(1):41-53. PubMed ID: 34496689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.